Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Daniel Park

Infectious Disease San Diego, CA Medical Doctor

NPI 1538371844 CMS profile 1090187

200 W Arbor Dr, Mc 8208, San Diego, CA 92103

Open in the dashboard

General payments

$2,292

134 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniel Park of San Diego, CA is reported in the CMS Open Payments database as having received $2,292 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $13 1
2023 General $287 11
2022 General $186 12
2021 General $413 33
2020 General $361 25
2019 General $1,032 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Park
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Daniel Park were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Daniel Park Infectious Disease median Middle half National median
2019 $1,032 $190 $60–$862 $163
2020 $361 $124 $32–$606 $114
2021 $413 $148 $38–$905 $132
2022 $186 $166 $50–$834 $149
2023 $287 $171 $57–$787 $160
2024 $13 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. ViiV Healthcare Company $1,279 55 payments
  2. Gilead Sciences, Inc. $489 48 payments
  3. Janssen Biotech, Inc. $316 25 payments
  4. Janssen Products, LP $119 1 payment
  5. Merck Sharp & Dohme Corporation $40 3 payments
  6. Janssen Pharmaceuticals, Inc $28 1 payment
  7. AbbVie, Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,263 133 payments
  2. Education $28 1 payment
Products named General payments · program years 2019–2024
  1. DOVATO $913 40 payments
  2. SYMTUZA $435 26 payments
  3. CABENUVA $212 9 payments
  4. TRIUMEQ $130 5 payments
  5. JULUCA $65 5 payments
  6. PIFELTRO $40 3 payments
  7. DIFICID $40 3 payments
  8. ISENTRESS $40 3 payments
  9. DELSTRIGO $40 3 payments
  10. RUKOBIA $25 1 payment
  11. Other $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record